<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2204245189
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1994
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Metronidazole intravenous infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METRONIDAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="B. BRAUN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            B. BRAUN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 971]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Medical Supplies And Services Co Ltd (Mediserv)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            B. BRAUN
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XD01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Metronidazole Intravenous Infusion 500 mg belongs to a group of<br />medicines known as antibiotics and is used to treat severe infections caused by bacteria that can be killed by the active substance metronidazole.<br />You may be given Metronidazole Intravenous Infusion 500 mg for the treatment or prevention of any of the following diseases:<br />&ndash; infections of the central nervous system such as local infection with pus (abscesses) in the brain, inflammation of the layers of tissue that cover the brain and the spinal cord (meningitis).<br />&ndash; infections of the lungs and layers of tissue that cover the lungs, such as lung infection (pneumonia) accompanied by tissue destruction, pneumonia following entry of stomach contents into the lungs, abscesses in the lungs,<br />&ndash; infections of the gastro-intestinal tract, such as inflammation of the internal lining of the abdomen and pelvic walls, abscesses in the liver, large bowel or rectal surgery, infections with pus in the abdomen and pelvis,<br />&ndash; infections of the female sex organs, such as inflammation within the womb, after removal of the womb, caesarean section, miscarriage accompanied by blood poisoning (sepsis), childbed fever,<br />&ndash; infections of the ears, nose and throat, and teeth, jaw and mouth, such as trench mouth.<br />&ndash; inflammation of the layers of tissue that covers the heart (endocarditis).<br />&ndash; infections of bones and joints, such as inflammation of the bone<br />marrow.<br />&ndash; bacterial infections that produce gas beneath the skin leading to tissue death (gas gangrene).<br />&ndash; blood poisoning arising from formation of a blood clot inside your<br />blood vessel (thrombosis) and inflamed veins.</p><p style="text-align:justify">If required, your treatment may be supplemented by other antibiotics.<br />Metronidazole Intravenous Infusion 5mg/ml&nbsp;mg may be given to you before operations to prevent infections.with what are known as anaerobic bacteria, mainly in gynaecology or surgery on stomach and gut.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>You must not be given Metronidazole Intravenous Infusion<br />5&nbsp;mg/ml</strong><br />&ndash; if you are allergic to metronidazole, other similar substances or any of the other ingredients of this medicine (listed in section 6).<br /><strong>Warnings and precautions</strong><br />Talk to your doctor before receiving Metronidazole Intravenous Infusion 5&nbsp;mg/ml . Please tell your doctor if you have:<br />&ndash; severe liver damage,<br />&ndash; a blood formation disorder or<br />&ndash; a disease of brain, spinal cord or nerves.<br />Therefore, your doctor will very carefully determine whether you should be treated with Metronidazole Intravenous Infusion 5&nbsp;mg/ml.<br />If convulsive fits or any other nerve affections (e.g. numbness in limbs) become apparent during therapy, your treatment will be stopped immediately.<br />In case of severe allergic responses (like anaphylactic shock), your<br />treatment will be stopped promptly.<br />Treatment with Metronidazole Intravenous Infusion 5&nbsp;mg/ml&nbsp;should not be longer than 10 days; the treatment period will only be extended in exceptional cases and if absolutely necessary. Repeat therapy with metronidazole will be restricted to cases where this is absolutely necessary. In such a case, you will be monitored particularly carefully.<br />Treatment must be stopped or revised immediately if you get severe diarrhoea which may be due to a severe large bowel disease called &ldquo;pseudomembranous colitis&rdquo; (See also section 4).</p><p style="text-align:justify">Cases of severe liver toxicity/acute liver failure, including cases with a fatal outcome, in patients with Cockayne syndrome have been reported with product containing metronidazole.<br />If you are affected by Cockayne syndrome, your doctor, pharmacist or nurse should also monitor your liver function frequently while you are being treated with metronidazole and afterwards.</p><p style="text-align:justify">Tell your doctor, pharmacist or nurse immediately and stop taking<br />metronidazole if you develop:<br />&bull; Stomach pain, anorexia, nausea, vomiting, fever, vague illness, fatigue, jaundice, dark urine, putty or mastic coloured stools or itching.<br />As prolonged use of metronidazole may impair blood formation (see section &ldquo;Possible side effects&rdquo;), your blood counts will be monitoredduring treatment.</p><p style="text-align:justify"><strong>Other medicines and Metronidazole Intravenous Infusion<br />5&nbsp;mg/ml</strong><br />Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p style="text-align:justify"><em>Amiodarone (used to treat irregular heartbeat)</em><br />When you receive this medicine, your heart function should be monitored. You should see your doctor, pharmacist or nurse if you notice any heart function abnormalities, dizziness or fainting.</p><p style="text-align:justify"><em>Barbiturates (the active substance in sleeping pills)</em><br />The duration of action of metronidazole is reduced by phenobarbital; therefore, your metronidazole dose may have to be increased.</p><p style="text-align:justify"><em>Birth control pills</em><br />Your birth control pill may be less reliable while you are being given<br />metronidazole.</p><p style="text-align:justify"><em>Busulfan</em><br />Metronidazole should not be given to patients receiving busulfan because busulfan levels in your blood will increase and toxic effects are more likely to occur.</p><p style="text-align:justify"><em>Carbamazepine (a drug for the treatment of epilepsy)</em><br />This combination also warrants caution because metronidazole may<br />increase the duration of action of carbamazepine.</p><p style="text-align:justify"><em>Cimetidine (a drug for the treatment of stomach disorders)</em><br />Cimetidine may reduce the elimination of metronidazole in isolated cases and your body.</p><p style="text-align:justify"><em>Vitamin K antagonists (drugs that inhibit blood clotting)</em><br />Metronidazole may enhance the blood clotting inhibition brought about by vitamin K antagonists, e.g. coumarins. So if you are taking a medicine that inhibits blood clotting (for example warfarin), you may need less of it during treatment with metronidazole.</p><p style="text-align:justify"><em>Ciclosporin (a drug used to suppress undesirable immune responses)</em><br />When ciclosporin is given together with metronidazole, the blood levels of ciclosporin may increase; your doctor will therefore have to adjust your ciclosporin dose as appropriate.</p><p style="text-align:justify"><em>Disulfiram (used in alcohol withdrawal therapy)</em><br />If you are taking disulfiram, you must not be given metronidazole, or disulfiram must be stopped. Combined use of these two drugs may lead to states of confusion up to the point of a serious mental disorder (psychosis).</p><p style="text-align:justify"><em>Fluorouracil (an anticancer drug)</em><br />The daily dose of Fluorouracil may have to be reduced when giving it together with Metronidazole because metronidazole may lead to an increase of the blood level of Fluorouracil.</p><p style="text-align:justify"><em>Lithium (used to treat mental illness)</em><br />Treatment with lithium preparations requires particularly careful<br />monitoring during treatment with metronidazole, and the dose of the lithium preparation may need to be re-adjusted.</p><p style="text-align:justify"><em>Mycophenolate mofetil (used for the prevention of rejection reactions after organ transplant)</em><br />Its effect may be weakened by metronidazole, so careful monitoring of the effect of the medicine is recommended.</p><p style="text-align:justify"><em>Phenytoin (a drug for the treatment of epilepsy</em></p><p style="text-align:justify">If you are taking phenytoin, your doctor will treat you with metronidazole only with caution because metronidazole may increase the duration of action of phenytoin. On the other hand, phenytoin may reduce the effect of metronidazole.</p><p style="text-align:justify"><em>Tacrolimus (used to suppress unwanted immune reactions)</em><br />The blood levels of this agent and your kidney function should be checked when starting and stopping treatment with metronidazole.</p><p style="text-align:justify"><strong>Metronidazole Intravenous Infusion 5&nbsp;mg/ml with alcohol</strong><br /><em>Alcohol</em><br />You must not drink any alcoholic beverages while you are being given metronidazole because this may cause intolerance reactions such as dizziness and vomiting.</p><p style="text-align:justify"><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or<br />planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p style="text-align:justify"><em>Contraception in males and females</em><br />If you are taking a birth-control pill, please refer to section &ldquo;Taking or using other medicines&rdquo;.</p><p style="text-align:justify"><em>Pregnancy</em><br />If you are pregnant, your doctor, will not treat you with metronidazole unless she/he considers this absolutely necessary. The pregnancy category<br />is category B.</p><p style="text-align:justify"><em>Breast-feeding</em><br />You should not breast-feed during treatment with metronidazole and not resume nursing for another 2&ndash;3 days thereafter because metronidazole passes into breast milk.</p><p style="text-align:justify"><em>Fertility</em><br />Animal studies only indicate a potential negative influence of<br />metronidazole on the male reproductive system if high doses lying well above the maximum recommended dose for humans were administered.</p><p style="text-align:justify"><strong>Driving and using machines</strong><br />You should not drive or use any machines while being treated with<br />metronidazole as metronidazole may impair alertness. This is even more the case when you have drunk alcohol.</p><p style="text-align:justify"><strong>Metronidazole Intravenous Infusion 5&nbsp;mg/ml contains<br />sodium</strong><br />This medicine contains 3.2 mg sodium (main component of cooking/table salt) in each ml.</p><p style="text-align:justify">This is equivalent to 0.16% of the recommended maximum daily dietary intake of sodium for an adult.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>Dosage</strong><br />Dosage depends on the nature and severity of your illness, your age and body weight, and your individual response to treatment.<br />The recommended usual dosages are:</p><p style="text-align:justify"><em>Adults and adolescents</em><br /><u>Treatment of infections:</u><br />Usually you will be given 300 ml of the medicine (corresponding to 1500 mg of metronidazole) on the first day of treatment.<br />From the second day of treatment onwards you will receive 200 ml of the medicine (corresponding to 1000 mg of metronidazole) every day.<br />As an alternative you may receive 100 ml of the medicine (corresponding to 500 mg of metronidazole) every 8 hours.<br />At the beginning of your treatment your doctor may give you an initial higher dose of metronidazole.<br />In most cases treatment will take 7 days. Only exceptionally treatment may be continued beyond this time.<br />You will be given a medicine containing 200 mg or 400 mg of this active ingredient in an 8 hourly rhythm as soon as feasible.</p><p style="text-align:justify"><em>Bacterial inflammation of the vagina</em><br />Adolescents: 400 mg twice daily for 5-7 days or 2000 mg as a single dose.</p><p style="text-align:justify"><em>Infection of the urinary system with a special germ named trichomonas vaginalis (trichomoniasis)</em><br />Adults and adolescents: 2000 mg as a single dose or 200 mg 3 times daily for 7 days or 400 mg twice daily for 5-7 days</p><p style="text-align:justify"><em>Infection with a germ called giardia lambia (giardiasis, beaver fever)</em><br />&gt; 10 years: 2000 mg once daily for 3 days, or 400 mg three times daily for 5 days, or 500 mg twice daily for 7 to 10 days<br />Alternatively, as expressed in mg per kg of body weight: 15-40 mg/kg/day divided in 2-3 doses.</p><p style="text-align:justify"><em>Infections with amoeboids</em><br />&gt; 10 years: 400 to 800 mg 3 times daily for 5-10 days<br />Alternatively, doses may be expressed by body weight: 35 to 50 mg/kg daily in 3 divided doses for 5 to 10 days, not to exceed 2400 mg/day</p><p style="text-align:justify">The dose will be the same for patients with kidney diseases.<br />For patients with liver diseases, lower doses may be required.<br />If you were treated by artificial kidney your doctor will adapt your dosage on the days of your treatment.</p><p style="text-align:justify"><u>Prevention of infections that might occur after operations</u><br />When used for prevention of infection in surgery, you may be given 500 mg of the medicine before the operation. The dose will be repeated 8 and 16 hours after the operation.<br />You will receive oral doses of 200 mg or 400 mg 8 hourly instead of this solution as soon as feasible.</p><p style="text-align:justify"><em>Use in children</em><br />Dosing in children is based on body weight (BW).</p><p style="text-align:justify"><u>Treatment of infections</u></p><p style="text-align:justify"><img alt="" width="412" height="335" src="data:image/png;base64,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" /></p><p style="text-align:justify">Usually treatment will take 7 days.</p><p style="text-align:justify"><em>Infection of the urinary system with a special germ named trichomonas vaginalis (trichomoniasis)</em></p><p style="text-align:justify">Children &lt; 10 years: 40 mg/kg orally as a single dose or 15-30 mg/<br />kg/day divided in 2-3 doses for 7 days; not to<br />exceed 2000 mg/dose</p><p style="text-align:justify"><em>Infection with a germ called giardia lambia (giardiasis, beaver fever)</em><br />Children 7 to 10 years: 1 OOOmg once daily for 3 days<br />Children 3 to 7 years: 600 to 800 mg once daily for 3 days<br />Children 1 to 3 years: 500 mg once daily for 3 days</p><p style="text-align:justify">Alternatively, as expressed in mg per kg of body weight:<br />15-40 mg/kg/day divided in 2-3 doses.</p><p style="text-align:justify"><em>Infections with amoeboids</em><br />Children 7 to 10 years: 200 to 400 mg 3 times daily for 5-10 days<br />Children 3 to 7 years: 100 to 200 mg 4 times daily for 5-10 days<br />Children 1 to 3 years: 100 to 200 mg 3 times daily for 5-10 days<br />Alternatively, doses may be expressed by body weight:<br />35 to 50 mg/kg daily in 3 divided doses for 5 to 10 days, not to exceed 2400 mg/day</p><p style="text-align:justify"><em>Therapy of infections caused by a germ called Helicobacter pylori in<br />children:</em><br />As a part of a combination therapy, 20 mg/kg/day not to exceed 500 mg twice daily for 7-14 days. Official guidelines should be consulted before initiating therapy.<br />&nbsp;</p><p style="text-align:justify"><u>Prevention of infections that might occur after operations:</u></p><p style="text-align:justify"><img alt="" width="408" height="122" src="data:image/png;base64,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" /></p><p style="text-align:justify"><em>Method of administration and duration of treatment</em><br />Metronidazole Intravenous Infusion 500 mg is administered through a drip directly into a vein (intravenous infusion).<br />The infusion of one bottle usually takes 60 minutes, but it should not be done within less than 20 minutes.<br />This medicine may be diluted in a suitable vehicle solution for infusion.<br />The entire metronidazole treatment period is usually 7 days and must not exceed 10 days unless this is absolutely necessary.<br />If you are concurrently receiving other antibiotics your doctor will give you those medicines separately.</p><p style="text-align:justify"><strong>If you receive more Metronidazole Intravenous Infusion 5&nbsp;mg/ml than you should</strong><br />As your dose is controlled by a doctor, pharmacist or nurse, it is unlikely that you will be given too much of this solution.<br />However, if accidentally you did receive too much of the solution,<br />undesirable effects, as described in the next section, may occur as signs or symptoms of an overdose.<br />There is no known specific antidote or specific treatment of a massive overdose, but metronidazole can be removed by treatment with artificial kidney (dialysis) from the body.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Side effects occur mostly at high doses or with prolonged use.</p><p style="text-align:justify"><strong>The following side effects may be serious and, therefore, require<br />immediate treatment:</strong><br /><u>Rare:</u><br />&ndash; Severe persistent diarrhoea (possibly a symptom of a severe bowel infection called pseudomembranous colitis, see below)<br />&ndash; Severe acute hypersensitivity reactions up to allergic shock<br />&ndash; Severe skin reactions</p><p style="text-align:justify"><u>Very rare:</u><br />&ndash; White blood cells and platelet counts may decrease during treatment (granulocytopenia, agranulocytosis, pancytopenia, thrombocytopenia). Regular monitoring of blood cell counts is necessary during prolonged<br />use.<br />&ndash; Brain disorders, lack of coordination<br />&ndash; Severe inflammatory rash on mucous membranes and the skin with fever, redness and blistering, in extremely rare cases up to skin<br />detachment over extended areas (Stevens-Johnson Syndrome, toxic<br />epidermal necrolysis)</p><p style="text-align:justify"><u>Not known:</u><br />&ndash; Mild to moderate hypersensitivity reactions, swelling of your face,<br />mouth, throat and/or tongue (angioedema)<br />&ndash; Gaze spasm, damage or inflammation of the nerves of your eyes<br />&ndash; Reduced white blood cell count (leucopenia), severe anaemia (aplastic anaemia)<br />&ndash; Seizures, nervous disorders such as numbness, pain, furry sensation or tingling in the arms or legs<br />&ndash; Brain inflammation not caused by bacteria (aseptic meningitis)<br />&ndash; Liver inflammation (hepatitis), yellowish or greenish pigmentation of the skin and whites of the eye (jaundice)<br />&ndash; Inflammation of the pancreas (isolated reports)</p><p style="text-align:justify">If seizures or signs of nervous disorders appear, you have to inform your doctor, pharmacist or nurse immediately.</p><p style="text-align:justify"><strong>Other side effects include</strong><br /><u>Common</u><br />&ndash; Infections with yeasts (e.g. genital infections)</p><p style="text-align:justify"><u>Uncommon</u><br />&ndash; Darkened urine (due to a product of metabolism of metronidazole)</p><p style="text-align:justify"><u>Rare</u><br />&ndash; Changes in electrocardiogram (ECG)</p><p style="text-align:justify"><u>Very rare:</u><br />&ndash; Psychotic disorders, including states of confusion, hallucination,<br />&ndash; Headache, dizziness, drowsiness, fever, disturbance of sight and<br />movement, giddiness, speech defects, convulsions<br />&ndash; Visual disturbances, e.g. double vision, short-sightedness<br />&ndash; Liver function disorders (such as elevated serum levels of certain<br />enzymes and bilirubin)<br />&ndash; Joint and muscle pain</p><p style="text-align:justify"><u>Not known:</u><br />&ndash; Vomiting, feeling sick, diarrhoea, inflammation of tongue or mouth, belching and bitter taste, metallic taste, pressure above the stomach, furry tongue<br />&ndash; Difficulty in swallowing<br />&ndash; Eating disorder (anorexia)<br />&ndash; Sad (depressed) mood<br />&ndash; Sleepiness or sleeplessness, muscle twitching,<br />&ndash; Reddening and itching of the skin (erythema multiforme)<br />&ndash; Vein wall irritation (to the point of inflamed veins and thrombosis) after intravenous administration, states of weakness, fever</p><p style="text-align:justify"><em>Emergency management of pseudomembranous enterocolitis</em><br />In the event of severe persistent diarrhoea, you must promptly inform your doctor because this may be due to pseudomembranous colitis, a serious condition that must be treated immediately. Your doctor will stop metronidazole and provide appropriate treatment.</p><p style="text-align:justify"><strong>You can also report side effects directly via<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />By reporting side effects you can help provide more information on the safety of this medicine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep this medicine out of the sight and reach of children.<br />Keep bottles in the carton in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the container and carton. The expiry date refers to the last day of that month.<br />Use only if the solution is clear and colourless or slightly yellowish and free of visible particles, and the bottle and closure are intact.<br />This medicinal product is intended for single use only. Discard any unused content after use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">- The active substance is metronidazole.<br />1 ml Metronidazole Intravenous Infusion&nbsp;solution for infusion<br />contains 5 mg metronidazole.<br />One 100-ml polyethylene bottle contains 500 mg metronidazole.<br />&ndash; The other ingredients are sodium chloride, disodium phosphate dodecahydrate, citric acid, water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Metronidazole Intravenous Infusion 5 mg/ml is a clear, colourless or slightly yellowish aqueous solution.
Metronidazole Intravenous Infusion 5 mg/ml is supplied in 100-ml polyethylene bottles.
The solution is supplied in packs of 10 or 20 bottles.Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />B.Braun Melsungen AG<br />Carl-Braun-Str. 1<br />34212 Melsungen, Germany</p><p><em>Postal address:</em><br />34209 Melsungen, Germany</p><p>Tel. +49-5661-71-0<br />Fax +49-5661-71-4567</p><p><strong>Manufacturer(s)</strong><br />B.Braun Melsungen AG&nbsp;<br />Carl-Braun-Str. 1&nbsp;<br />34212 Melsungen, Germany&nbsp;</p><p>B.Braun Medical, S.A.<br />Carretera de Terrassa 121<br />08191 Rub&iacute;, Barcelona, Spain</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="text-align:justify">ينتمي مترونيدازول 5 مجم/مل&nbsp;المخصص للتسريب الوريدي إلى مجموعة من الأدویة تُعرف بالمضادات الحيوية، ویُستخدم في علاج حالات العدوى الشديدة التي تسببها&nbsp;بكتيريا، والتي يمكن&nbsp;القضاء عليها&nbsp;بواسطة<br />المادة الفعالة مترونيدازول.</p><p style="text-align:justify">قد يتم إعطاؤك مترونيدازول 500 مجم المخصص للتسريب الوريدي لعلاج أي من الأمراض التالية أو الوقاية منها:</p><p style="text-align:justify"><br />- حالات العدوى التي تصيب&nbsp;الجهاز العصبي المركزي مثل عدوى موضعية&nbsp;تحتوي على صديد&nbsp;(خراجات) في الدماغ، التهاب طبقات الأنسجة التي تغطي الدماغ والنخاع الشوكي (التهاب السحايا)<br />- حالات العدوى التي تصيب&nbsp;الرئتين&nbsp;وطبقات الأنسجة التي تغطي الرئتين، مثل عدوى الرئتين (الالتهاب الرئوي) المصحوبة بتدمير الأنسجة، الالتهاب الرئوي الذي یتبع دخول محتویات المعدة إلى الرئتین، والخراجات في الرئتین،<br />- حالات العدوى التي تصیب الجھاز الھضمي، مثل التھاب البطانة الداخلیة للبطن وجدران الحوض، خراجات الكبد أو الأمعاء الغلیظة، أو بعد جراحة في المستقیم، حالات العدوى المصحوبة بالصدید في البطن والحوض،<br />- حالات العدوى في الأعضاء التناسلیة لدى المرأة، مثل الإصابة بالتھاب داخل الرحم، بعد إزالة الرحم، الإصابة بالتھاب بعد الولادة القیصریة، الإجھاض الذي یصحبھ تسمم الدم (الإنتان)، وحمى النفاس،<br />- حالات العدوى التي تصیب الأذنین والأنف والحلق، والأسنان، والفك والفم مثل التھاب اللثة الناخر<br />- التھاب طبقات الأنسجة التي تغطي القلب (التهاب الشغاف)<br />- حالات العدوى التي تصیب العظام والمفاصل، مثل التھاب نخاع العظم<br />- حالات العدوى البكتيرية التي تنتج غازًا تحت الجلد مؤدية إلى موت الأنسجة (الغنغرينة الغازية)<br />- تسمم الدم الناتج عن تكوّن جلطة دموية داخل أوعيتك الدموية (الخثار) والتھاب الأوردة</p><p style="text-align:justify">إذا كان ذلك ضروریا، فقد یتطلب إتمام العلاج إضافة مضادات حیویة أخرى.</p><p style="text-align:justify">یمكن إعطاؤك مترونيدازول 500 مجم المخصص للتسريب الوريدي قبل العملیات الجراحية لمنع حدوث حالات العدوى بالبكتيريا المعروفة باسم البكتیریا اللاهوائية، وبشكل رئیسي في الجراحات النسائیة، أو عند الخضوع للجراحة في المعدة والأمعاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify"><strong>يجب عدم إعطاؤك مترونيدازول 500 مجم المخصص للتسريب الوريدي في الحالات التالية:</strong><br />- إذا كنت مصابًا بالحساسیة تجاه مترونیدازول، أو تجاه المواد المشابھة الأخرى، أو تجاه أي من المكونات&nbsp;الأخرى لھذا الدواء (المدرجة في القسم 6).</p><p style="text-align:justify"><strong>تحذیرات واحتیاطات</strong><br />تحدث إلى طبيبك قبل تلقي مترونيدازول 500 مجم المخصص للتسريب الوريدي. يُرجى إخبار طبيبك إذا كنت مصابًا بأي مما يلي:<br />- تلف شدید في الكبد، أو<br />- اضطراب في تكون الدم، أو<br />- مرض في الدماغ، أو الحبل الشوكي، أو الأعصاب.</p><p style="text-align:justify">وبناءً على ذلك، سیتوخى طبیبك الحذر عند تحدید ما إذا كان ینبغي علاجك باستخدام مترونيدازول 500 مجم المخصص للتسريب الوريدي أم لا.</p><p style="text-align:justify">إذا ظھرت نوبات تشنج، أو أي إصابات عصبیة أخرى (مثل تنمیل الأطراف) أثناء العلاج، فسيتم إيقاف علاجك فورًا.</p><p style="text-align:justify">في حالة الإصابة باستجابات حساسية شديدة (مثل الصدمة التأقية)، سيتم إيقاف علاجك فورًا.</p><p style="text-align:justify">ینبغي ألا تزيد مدة العلاج باستخدام مترونيدازول 500 مجم المخصص للتسريب الوريدي عن 10 أيام؛ وسیتم تمدید فترة العلاج فقط في حالات استثنائیة، وفي حالة الضرورة القصوى. سیكون تكرار العلاج باستخدام<br />مترونیدازول قاصرًا على الحالات التي تتطلب ذلك لضرورة قصوى. وفي مثل ھذه الحالات، ستتم مراقبتك بعنایة.</p><p style="text-align:justify">يجب إيقاف العلاج، أو إعادة النظر فيه فورًا، إذا أصبت بإسهال شديد قد يكون ناتجًا عن مرض شدید في الأمعاء الغلیظة یسمى &quot;التھاب القولون الغشائي الكاذب&quot; (انظر أيضًا القسم 4).&nbsp;</p><p style="text-align:justify">تم الإبلاغ عن حالات تسمم كبدي شديد/فشل كبدي حاد، بما في ذلك حالات ذات نتائج مميتة، لدى المرضى المصابين بمتلازمة كوكاين، عند استخدام منتج يحتوي على مترونيدازول.</p><p style="text-align:justify">إذا كنت مصابًا بمتلازمة كوكاين، ينبغي أيضًا لطبيبك أو الصيدلي أو الممرضة أن يقوموا بمراقبة وظائف الكبد لديك بشكل متكرر، طوال الفترة التي تخضع فيها للعلاج باستخدام مترونيدازول وبعدها.</p><p style="text-align:justify">أ<u>خبر طبيبك أو الصيدلي أو الممرضة على الفور وتوقف عن أخذ مترونيدازول إذا أُصبت بالحالات التالية:</u><br />&bull; ألم في المعدة، أو فقدان شهية، أو غثيان، أو قيء، أو حمى، أو مرض غامض، أو إرهاق، أو يرقان، أو بول داكن، أو تغير لون البراز إلى الأصفر الباهت، أو الحكة.</p><p style="text-align:justify">حیث إن الاستخدام المطول لمترونیدازول قد يُحدث خللاً في عملیة تكون الدم (انظر قسم &quot;الآثار الجانبیة المحتملة&quot;)، فستتم مراقبة تعداد خلایا الدم لدیك أثناء العلاج.</p><p style="text-align:justify"><strong>الأدویة الأخرى ومترونيدازول 500 مجم المخصص للتسريب الوريدي</strong><br />یُرجى إخبار طبیبك أو الصیدلي إذا كنت تتناول في الوقت الحالي، أو قد تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى، بما في ذلك الأدویة التي یتم الحصول علیھا دون وصفة طبیة.</p><p style="text-align:justify">أ<em>میودارون (یُستخدم لعلاج عدم انتظام ضربات القلب)</em><br />عندما تتلقى ھذا الدواء، ینبغي أن تتم مراقبة وظائف قلبك. ینبغي أن تزور طبیبك أو الصيدلي أو الممرضة إذا لاحظت أي اضطرابات في وظائف القلب أو دوخة أو إغماء.</p><p style="text-align:justify"><em>باربیتورات (المادة الفعالة في الحبوب المنومة)</em><br />تقل فترة تأثیر مترونیدازول بفعل فینوباربیتال؛ ولذلك فقد یتطلب الأمر زیادة جرعة مترونیدازول التي تتلقاھا.</p><p style="text-align:justify"><em>حبوب منع الحمل</em><br />قد یقل مفعول حبوب الحمل التي تتناولینھا بینما تتلقین مترونیدازول.</p><p style="text-align:justify"><em>بوسلفان</em><br />ینبغي عدم إعطاء مترونیدازول للمرضى الذین یتلقون بوسلفان، لأن مستويات عقار بوسلفان ستزيد في دمك، وستكون هناك احتمالية أكبر لحدوث آثار سامة.</p><p style="text-align:justify">كر<em>بامازیبین (عقار لعلاج الصرع)</em><br />یتطلب استخدام ھذه التركیبة أیضًا توخي الحذر لأنھ یمكن أن یتسبب مترونیدازول في زیادة فترة تأثیر كربامازیبین.</p><p style="text-align:justify"><em>سیمیتیدین (عقار لعلاج اضطرابات المعدة)</em><br />في حالات فردیة قد یخفض سیمیتیدین من القدرة على التخلص من مترونیدازول، وبالتالي یؤدي إلى زیادةةتركیزات مترونیدازول في جسمك.</p><p style="text-align:justify"><em>مضادات فيتامين ك (عقاقیر تثبط من تخثر الدم)</em><br />قد یعزز مترونیدازول من عملیة تثبیط تخثر الدم التي تتسبب فیھا مضادات فيتامين ك مثل مشتقات الكومارین. لذا إذا كنت تتناول دواءً یُثبط تخثر الدم (مثل وارفارین)، فقد تحتاج إلى تقلیل جرعتھ أثناء العلاج باستخدام مترونیدازول.</p><p style="text-align:justify"><em>سیكلوسبورین (عقار یستخدم لكبت الاستجابات المناعیة غیر المرغوب فیھا)</em><br />عندما یتم إعطاء سیكلوسبورین بالتزامن مع مترونیدازول، قد تزداد مستویات سیكلوسبورین في الدم؛ ولذلك سیقوم طبیبك بتعدیل جرعة سیكلوسبورین التي تتلقاھا حسب الحاجة.</p><p style="text-align:justify">د<em>يسَلفيرام (يُستخدم في علاج أعراض سحب الكحول)</em><br />إذا كنت تتناول ديسَلفيرام، يجب ألا تُعطى مترونیدازول، أو یجب إیقاف تناول ديسَلفيرام. الاستخدام المتزامن لھذین العقارین قد یؤدي إلى الإصابة بحالات من التشوش، وقد تزید إلى حد الإصابة باضطراب عقلي خطیر (الذهان)</p><p style="text-align:justify"><em>فلورویوراسیل (عقار مضاد للسرطان)</em><br />قد یلزم تخفیض الجرعة الیومیة من فلورویوراسیل عند إعطائھ بالتزامن مع مترونیدازول، لأن مترونیدازول قد یؤدي إلى زیادة مستویات فلورویوراسیل في الدم.</p><p style="text-align:justify"><em>اللیثیوم (یُستخدم لعلاج المرض العقلي)</em><br />إن العلاج باستخدام مستحضرات اللیثیوم یتطلب المراقبة بعنایة، وبشكل خاص أثناء العلاج باستخدام مترونیدازول، وقد یلزم إعادة ضبط جرعة مستحضر اللیثیوم.</p><p style="text-align:justify"><em>میكوفینولات موفیتیل (يُستخدم لمنع حدوث تفاعلات الرفض بعد عملیات زراعة الأعضاء)</em><br />قد یضعف مترونیدازول من تأثیره، لذا یوصى بمراقبة تأثیر الدواء بعنایة.</p><p style="text-align:justify"><em>فنیتوین (عقار لعلاج الصرع)</em><br />إذا كنت تتناول فنیتوین، فسیتوخى طبیبك الحذر عند علاجك باستخدام مترونیدازول، لأن مترونیدازول قد یزید من فترة تأثیر فنیتوین. وعلى الجانب الآخر، قد یخفض فنیتوین من تأثیر مترونیدازول.</p><p style="text-align:justify"><em>تاكرولیمَس (يُستخدم لكبت التفاعلات المناعیة غیر المرغوب فیھا)</em><br />ینبغي التحقق من مستویات ھذا العامل في الدم، ومن وظائف الكلى لدیك، عند بدء العلاج باستخدام مترونیدازول وعند إیقافھ.</p><p style="text-align:justify"><strong>مترونيدازول 500 مجم المخصص للتسريب الوريدي مع الكحول</strong><br />الكحول<br />ینبغي ألا تشرب أي مشروبات كحولیة بینما یتم إعطاؤك مترونیدازول، لأن ھذا قد یتسبب في حدوث تفاعلات عدم تحمل مثل الدوخة والتقیؤ.</p><p style="text-align:justify">ا<strong>لحمل والرضاعة الطبیعیة والخصوبة</strong><br />إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ حامل، أو تخططين للحمل، فاطلبي من طبيبك أو الصيدلي أو الممرضة المشورة قبل أخذ هذا الدواء.</p><p style="text-align:justify">موانع الحمل لدى الذكور والإناث<br />إذا كنت تتناولین حبوبًا لمنع الحمل، يُرجى مراجعة قسم &quot;تناول أو استخدام أدویة أخرى&quot;.</p><p style="text-align:justify">الحمل<br />إذا كنتِ حاملًا، فلن يقوم طبيبك بمعالجتك باستخدام مترونیدازول، ما لم يرَ ضرورةً قصوى لذلك. فئة الحمل<br />هي الفئة ب.</p><p style="text-align:justify">الرضاعة الطبیعیة<br />ینبغي ألا تقومي بالرضاعة الطبیعیة أثناء العلاج باستخدام مترونیدازول، وألا تواصلي الرضاعة بعد العلاج لمدة يومين إلى 3 أیام، لأن مترونیدازول یُفرز في لبن الأم.</p><p style="text-align:justify">الخصوبة<br />تشیر الدراسات التي أجریت على الحیوانات فقط، إلى تأثیر سلبي محتمل لمترونیدازول على الجھاز التناسلي في الرجال، في حالة إعطاء جرعات عالیة تزید بشكل كبیر عن الحد الأقصى للجرعة الموصى بھا للبشر.</p><p style="text-align:justify"><strong>القیادة واستخدام الآلات</strong><br />ینبغي ألا تقود أو تستخدم أي آلات بینما یتم علاجك باستخدام مترونیدازول، لأنھ قد یضعف الانتباه. ویزید ھذا التأثیر بصفة خاصةً عندما تكون قد تناولت المشروبات الكحولیة.</p><p style="text-align:justify"><strong>يحتوي هذا الدواء على 3.2 مجم من الصوديوم</strong> (المكون الرئيسي لملح الطعام/المائدة) في كل مل. هذا يعادل نسبة % 0.16 من أقصى مدخول غذائي يومي للصوديوم الموصى به للشخص البالغ.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify"><strong>الجرعة</strong><br />تعتمد الجرعة على طبیعة وشدة مرضك، وعمرك، ووزن جسمك، واستجابتك الشخصیة للعلاج.</p><p style="text-align:justify">الجرعات المعتادة الموصى بھا ھي:</p><p style="text-align:justify">البالغون والمراھقون</p><p style="text-align:justify"><u>علاج حالات العدوى:</u><br />في الغالب سيتم إعطاؤك 300 مل من الدواء )ما يعادل 1500 مجم من مترونیدازول( في اليوم الأول من العلاج.<br />بدءًا من الیوم الثاني في العلاج فما بعده، ستتلقى 200 مل من الدواء (ما يعادل 1000 مجم من مترونیدازول) كل يوم. كبديل، قد تتلقى 100 مل من الدواء (ما يعادل 500 مجم من مترونیدازول) كل 8 ساعات.في بدایة علاجك، قد یعطیك طبیبك جرعة مبدئیة أعلى من مترونیدازول.</p><p style="text-align:justify">سوف یستغرق العلاج 7 أيام في معظم الحالات. فقط في حالات استثنائیة قد یستمر العلاج لفترة تتعدى تلك المدة.</p><p style="text-align:justify">سيتم إعطاؤك دواءً يحتوي على 200 مجم أو 400 مجم من هذه المادة الفعالة بصورة منتظمة كل 8 ساعات<br />في أقرب وقت ممكن.</p><p style="text-align:justify">التهاب بكتيري في المهبل<br />المراهقات: 400 مجم مرتين يوميًا لمدة تتراوح من 5 إلى 7 أيام أو 2000 مجم كجرعة أحادية.</p><p style="text-align:justify">عدوى الجهاز البولي بجرثومة خاصة تسمى المشعَّرة المهبلية (داء المشعَّرات)<br />البالغات والمراهقات: 2000 مجم كجرعة أحادية، أو 200 مجم 3 مرات يوميًا لمدة 7 أيام، أو 400 مجم مرتين يوميًا لمدة تتراوح من 5 إلى 7 أيام</p><p style="text-align:justify">عدوى بجرثومة تسمى الجياردية اللمبِلِيَّة (داء الجيارديَّات أو حمى القندس)<br />أكبر من 10 أعوام: 2000 مجم مرة يوميًا لمدة 3 أيام، أو 400 مجم ثلاث مرات يوميًا لمدة 5 أيام، أو 500 مجم مرتين يوميًا لمدة تتراوح من 7 إلى 10 أيام<br />أو على النحو المُوضح بالمجم لكل كجم من وزن الجسم: 40-15 مجم/كجم/اليوم تُقسم على جرعتين أو 3 جرعات.</p><p style="text-align:justify">حالات العدوى بشبيهات الأميبا<br />أكبر من 10 أعوام: من 400 إلى 800 مجم 3 مرات يوميًا لمدة تتراوح من 5 إلى 10 أيام<br />أو يمكن التعبير عن الجرعات حسب وزن الجسم: من 35 إلى 50 مجم/كجم يوميًا مُقسمة على 3 جرعات لمدة تتراوح من 5 إلى 10 أيام، على ألا تتجاوز 2400 مجم/يوم</p><p style="text-align:justify">سیتلقى المرضى المصابون بأمراض في الكلى الجرعة نفسھا.<br />قد یلزم تخفیض الجرعة للأشخاص المصابین بأمراض في الكبد.</p><p style="text-align:justify">إذا كان قد تم علاجك بواسطة الكلیة الصناعیة، فسیقوم طبیبك بتقسیم جرعتك على أیام علاجك.</p><p style="text-align:justify"><u>الوقایة من حالات العدوى التي قد تحدث بعد العملیات</u><br />عند استخدامھ لمنع الإصابة بالعدوى أثناء الجراحة، قد تُعطى 500 مجم من الدواء قبل العملية. سيتم تكرار الجرعة كل 8 ساعات وكل 16 ساعة بعد العملية.<br />ستتلقى جرعات عن طريق الفم قدرها 200 مجم أو 400 مجم كل 8 ساعات بدلًا من هذا المحلول في أقرب وقت ممكن.</p><p style="text-align:justify">الاستخدام لدى الأطفال<br />یتم تحدید الجرعة في الأطفال بناءًا على وزن الجسم.</p><p style="text-align:justify"><strong>علاج حالات العدوى:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td style="width:199px">العمر</td><td style="width:231px">الجرعة</td></tr><tr><td style="width:199px">8 أسابيع إلى 12 عامًا</td><td style="width:231px">30-20 مجم من مترونیدازول لكل كجم من وزن الجسم يوميًا، كجرعة واحدة، أو تُقسم إلى 7.5 مجم من مترونیدازول لكل كجم من وزن الجسم كل 8 ساعات.<br />یمكن زیادة الجرعة الیومیة إلى 40 مجم من مترونیدازول لكل&nbsp;كجم من وزن الجسم، في حالة العدوى الشدیدة.</td></tr><tr><td style="width:199px">أقل من 8 أسابيع</td><td style="width:231px">15 مجم من مترونیدازول لكل كجم من وزن الجسم كجرعة واحدة يوميًا، أو تُقسم إلى 7.5 مجم من مترونیدازول لكل كجم من وزن الجسم كل 12 ساعة.</td></tr><tr><td style="width:199px">حدیثو الولادة الذین تقل فترة حملھم عن 40 أسبوعًا</td><td style="width:231px">لأن مترونیدازول قد یتراكم لدى ھؤلاء المرضى خلال الأسبوع الأول من الحیاة، فستتم مراقبة تركیزه في الدم بعد&nbsp;بضعة أیام من العلاج</td></tr></tbody></table><p style="text-align:justify">في المعتاد، سیستغرق العلاج 7 أیام.</p><p style="text-align:justify">عدوى الجهاز البولي بجرثومة خاصة تسمى المشعَّرة المهبلية (داء المشعَّرات)<br />الأطفال بعمر أقل من 10 أعوام: 40 مجم/كجم عن طريق الفم كجرعة أحادية أو 30-15 مجم/كجم/اليوم مُقسمة على جرعتين أو 3 جرعات لمدة 7 أيام؛ على ألا تتجاوز 2000 مجم/الجرعة</p><p style="text-align:justify">عدوى بجرثومة تسمى الجياردية اللمبِلِيَّة (داء الجيارديَّات أو حمى القندس)<br />الأطفال من عمر 7 حتى 10 أعوام: 1000 مجم مرة يوميًا لمدة 3 أيام<br />الأطفال من عمر 3 حتى 7 أعوام: من 600 إلى 800 مجم مرة واحدة يوميًا لمدة 3 أيام<br />الأطفال بدءًا من عمر عام حتى 3 أعوام: 500 مجم مرة واحدة يوميًا لمدة 3 أيام</p><p style="text-align:justify">أو على النحو الموضح بالمجم لكل كجم من وزن الجسم: 40-15 مجم/كجم/اليوم مُقسمة على جرعتين أو 3 جرعات.</p><p style="text-align:justify">حالات العدوى بشبيهات الأميبا<br />الأطفال من عمر 7 حتى 10 أعوام: من 200 إلى 400 مجم 3 مرات يوميًا لمدة تتراوح من 5 إلى 10 أيام<br />الأطفال من عمر 3 حتى 7 أعوام: من 100 إلى 200 مجم 4 مرات يوميًا لمدة تتراوح من 5 إلى 10 أيام<br />الأطفال بدءًا من عمر عام حتى 3 أعوام: من 100 إلى 200 مجم 3 مرات يوميًا لمدة تتراوح من 5 إلى 10 أيام<br />أو يمكن التعبير عن الجرعات حسب وزن الجسم: من 35 إلى 50 مجم/كجم يوميًا مُقسمة على 3 جرعات لمدة تتراوح من 5 إلى 10 أيام، على ألا تتجاوز 2400 مجم/اليوم</p><p style="text-align:justify">علاج حالات العدوى الناجمة عن جرثومة تُسمى الملوية البوابية لدى الأطفال:<br />كجزء من علاج مركب، يتم أخذ جرعة 20 مجم/كجم/اليوم، على ألا تتجاوز 500 مجم مرتين يوميًا لمدة تتراوح من 7 أيام إلى 14 يومًا.<br />ينبغي الرجوع إلى الإرشادات الرسمية قبل البدء في تلقي العلاج</p><p style="text-align:justify"><u>الوقایة من حالات العدوى التي قد تحدث بعد العملیات:</u></p><p style="text-align:justify"><img alt="" width="413" height="132" src="data:image/png;base64,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" /></p><p style="text-align:justify"><strong><em>طریقة الاستعمال وفترة العلاج</em></strong></p><p style="text-align:justify">يُعطى مترونيدازول 500 مجم المخصص للتسريب الوريدي من خلال التقطير في أحد الأوردة مباشرة (التسريب الوريدي).</p><p style="text-align:justify">عادة ما یستغرق تسریب زجاجة واحدة 60 دقيقة، ولكن ینبغي ألا یتم التسریب خلال أقل من 20 دقيقة.</p><p style="text-align:justify">یمكن تخفیف ھذا الدواء في محلول وسیط لیتم تسریبھ.</p><p style="text-align:justify">عادةً ما تكون فترة العلاج باستخدام مترونیدازول بالكامل 7 أيام، ويجب ألا تزيد عن 10 أيام ما لم تكن ھناك ضرورة قصوى لذلك.</p><p style="text-align:justify">إذا كنت تتلقى مضادات حیویة أخرى بالتزامن مع ھذا الدواء، فسیقوم طبیبك بإعطائك تلك الأدویة بشكل منفصل.</p><p style="text-align:justify"><strong>إذا تلقيت كمية أكثر مما ينبغي من مترونيدازول 500 مجم المخصص للتسريب الوريدي</strong><br />بما أن جرعتك تخضع لمراقبة طبيب أو صيدلي أو ممرضة، فإنك على الأرجح لن تتلقى كمية أكبر مما ينبغي من هذا المحلول.</p><p style="text-align:justify">لكن إذا تلقيت كمية أكبر مما ينبغي من هذا المحلول عن طريق الخطأ، فقد تحدث آثار غیر مرغوب فیھا في صورة علامات أو أعراض للجرعة المفرطة، كما ھو موضح في القسم التالي.</p><p style="text-align:justify">لا یوجد تریاق أو علاج معروف بالتحدید لعلاج الجرعة المفرطة جدًا، ولكن یمكن إزالة مترونیدازول من الجسم من خلال العلاج باستخدام كلیة صناعیة (غسيل كلوي).</p><p style="text-align:justify">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">كما ھو الحال مع جمیع الأدویة، یمكن أن یسبب ھذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p style="text-align:justify">غالبًا ما تحدث الآثار الجانبية عند تلقي جرعات عالية أو عند الاستخدام المُطول للدواء.</p><p style="text-align:justify"><strong>قد تكون الآثار الجانبیة التالیة خطیرة، ولذلك قد تتطلب العلاج الفوري:</strong><br /><u>نادرة:</u><br />- إسهال شديد مستمر (يُحتمل أن يكون عرضًا لعدوى شديدة في الأمعاء تُسمى التھاب القولون الغشائي الكاذب، انظر أدناه)<br />- تفاعلات فرط حساسیة حادة وشدیدة، تصل إلى الإصابة بصدمة أرجیة<br />- تفاعلات جلدية شديدة</p><p style="text-align:justify"><u>نادرة جدًا:</u><br />- قد ینخفض تعداد خلایا الدم البیضاء، والصفائح الدمویة أثناء العلاج (قلة المحببات، ندرة المحببات، قلة الكریات الشاملة في الدم، قلة الصفیحات). تُعد المراقبة المنتظمة لتعداد خلایا الدم ضروریة أثناء الاستخدام المطول.<br />- اضطرابات الدماغ، عدم التوافق بين حركات الجسم<br />- طفح جلدي التھابي شدید على الأغشیة المخاطیة والجلد، مع الحمى والاحمرار وظھور البثور، وفي حالات نادرة للغاية قد يصل الأمر إلى انفصال الجلد على نطاق مساحات ممتدة (متلازمة ستیفن جونسون، تقشر الأنسجة المتموتة البشرویة التسممي)</p><p style="text-align:justify"><u>غير معروف:</u><br />- تفاعلات حساسیة خفیفة إلى متوسطة، تورم الوجھ والفم والحلق، و/أو اللسان (الوذمة الوعائیة)<br />- التشنج البصري، تلف أو التھاب أعصاب عینیك<br />- انخفاض تعداد خلایا الدم البیضاء )قلة الكریات البیض(، الأنیمیا الشدیدة (فقر الدم اللاتنسجي)<br />- النوبات، الاضطرابات العصبیة مثل التنمیل، أو الألم، أو إحساس فروي (یشبھ الفرو)، أو الوخز في الذراعین أو الساقین<br />- التهاب الدماغ غير الناتج عن البكتيريا (التهاب السحايا العقيم)<br />- التهاب الكبد (الالتهاب الكبدي).&nbsp;اصفرار أو اخضرار لون الجلد وبياض العينين (اليرقان)<br />- التهاب البنكرياس (تقارير فردية)</p><p style="text-align:justify">في حالة حدوث نوبات أو ظهور علامات تدل على الإصابة باضطرابات عصبية، ينبغي عليك إخطار طبيبك أو الصيدلي أو الممرضة على الفور.</p><p style="text-align:justify"><strong>تتضمن الآثار الجانبیة الأخرى:</strong></p><p style="text-align:justify"><u>شائعة:</u><br />&ndash; حالات العدوى بالخمائر (مثل حالات عدوى الجھاز التناسلي)</p><p style="text-align:justify"><u>غير شائعة</u><br />- البول الداكن (سبب أحد نواتج أيض مترونيدازول)</p><p style="text-align:justify"><u>نادرة:</u><br />&nbsp;تغیرات في مخطط كھربیة القلب (ECG)</p><p style="text-align:justify"><u>نادرة جدًا:</u><br />- اضطرابات ذھانیة، بما في ذلك حالات من التشوش والھلاوس،<br />- صداع، دوخة، دوار، حمى، اضطراب في الرؤیة والحركة، عیوب الكلام، تشنجات<br />- اضطرابات بصریة، مثل الرؤیة المزدوجة، قصر النظر<br />- اضطرابات وظائف الكبد (مثل ارتفاع مستویات بعض الإنزیمات ومستویات الصفراء في المصل)<br />- ألم المفاصل والعضلات</p><p style="text-align:justify"><u>غير معروف:</u><br />- القيء، الشعور برغبة في التقیؤ، الإسھال، التھاب اللسان أو الفم، التجشؤ وتذوق طعم مر، طعم معدني، الشعور بضغط فوق المعدة، اللسان المُفَرَّى<br />- صعوبة في البلع<br />- اضطراب في الأكل (فقدان الشھیة)<br />- المزاج الحزین (المكتئب)<br />- النعاس أو الأرق، ارتعاش العضلات،<br />- الشعور بحكة في الجلد أو احمراره )الحمامى عدیدة الأشكال(<br />- تھیج جدار الورید )إلى الدرجة التي تؤدي إلى التھاب الأوردة وحدوث تخثر بھا( بعد الإعطاء الوریدي، وحالات من الضعف، الحمى</p><p style="text-align:justify">الإدارة في حالات الطوارئ لحالة الالتھاب المعوي القولوني الغشائي الكاذب<br />في حالة الإسھال الشدید المستمر، یجب أن تقوم فورًا بإبلاغ طبیبك لأنھ قد یكون بسبب التھاب القولون الغشائي الكاذب، وھي حالة خطیرة یجب علاجھا فورًا. سیقوم طبیبك بإیقاف العلاج باستخدام مترونیدازول وتقدیم العلاج الملائم.</p><p style="text-align:justify"><strong>بإمكانك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عبر<br />(NPC)&nbsp;المركز الوطني للتيقظ والسلامة الدوائية<br />فاكس: 7662-205-11- 966+<br />اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الرقم 2038222-11-966+ تحويلة :<br />2317-2356-2353-2354-2334-2340<br />رقم الهاتف المجاني: 8002490000<br />البريد الإلكتروني: npc.drug@sfda.gov.sa&nbsp;<br />الموقع الإلكتروني: www.sfda.gov.sa/npc&nbsp;<br />بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</strong></p><p style="text-align:justify">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">احفظ ھذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p style="text-align:justify">احفظ الزجاجات في العبوة الكرتونية حتى تحميها من الضوء.</p><p style="text-align:justify">لا تستخدم ھذا الدواء بعد مرور تاریخ انتھاء الصلاحیة المدون على الحاویة والعلبة الكرتونیة. یشیر تاریخ انتھاء الصلاحیة إلى آخر یوم من ذلك الشھر.</p><p style="text-align:justify">استخدم ھذا الدواء فقط إذا كان المحلول رائقًا وعديم اللون، أو يميل إلى الأصفر قليلًا، وخاليًا من الجسیمات المرئیة، وكانت الزجاجة والسدادة سلیمین.</p><p style="text-align:justify">ھذا المنتج الدوائي مخصص للاستخدام لمرة واحدة فقط. تخلص من أي محتوى غیر مستخدم بعد الاستخدام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">محتويات مترونيدازول 500 مجم المخصص للتسريب الوريدي<br />&ndash; المادة الفعالة ھي مترونیدازول.<br />1 مل&nbsp;یحتوي على 5 مجم من مترونیدازول.<br />تحتوي قارورة البولي إيثيلين سعة 100 مل على 500 مجم مترونیدازول.<br />&ndash; المكونات الأخرى ھي كلورید الصودیوم، فوسفات ثنائي الصودیوم ثنائي عشر الھیدرات، حمض الستریك، ماء للحقن<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>شكل مترونيدازول 500 مجم المخصص للتسريب الوريدي ومحتويات العبوة مترونيدازول 500 مجم المخصص للتسريب الوريدي</strong> ھو محلول مائي رائق عدیم اللون، أو مائل إلى الأصفر قليلًا. یتم تورید مترونيدازول 500 مجم المخصص للتسريب الوريدي في زجاجات من البولي إیثیلین سعة 100 مل. یتم تورید المحلول في عبوات تحتوي على 10 أو 20 زجاجة. قد لا تُطرح العبوات من كل الأحجام في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left">B.Braun Melsungen AG<br />Carl-Braun-Str. 1<br />34212 Melsungen, Germany</p><p dir="ltr" style="text-align:left"><em>العنوان البريدي:</em><br />34209Melsungen, Germany</p><p style="text-align:left">Tel. +49-5661-71-0<br />Fax +49-5661-71-4567</p><p dir="ltr" style="text-align:left">B.Braun Medical, S.A.<br />Carretera de Terrassa 121<br />08191 Rub&iacute;, Barcelona, Spain</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Metronidazole Intravenous Infusion 5 mg/ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of solution contains 5 mg of metronidazole
100 ml of solution contain 500 mg of metronidazole

Excipients with known effect:
1 ml solution contains
Sodium chloride 7.4 mg

Electrolyte content (per 100 ml):
Sodium 14 mmol
Chloride 13 mmol
Disodium phosphate dodecahydrate 1.5 mg

For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion;
Clear, colourless or slightly yellowish aqueous solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Treatment and prophylaxis of infections caused by metronidazole<br />susceptible microorganisms (mainly anaerobic bacteria). See section<br />5.1 for further information.<br />Metronidazole Intravenous Infusion 5 mg/ml is indicated in adults<br />and children for the following indications:<br />&bull; infections of the central nervous system (e. g. brain abscess,<br />meningitis)<br />&bull; infections of lung and pleura (e. g. necrotising pneumonia, aspiration<br />pneumonia, lung abscess)<br />&bull; endocarditis<br />&bull; infections in the gastrointestinal tract and the abdominal area<br />(e.g. peritonitis, liver abscess, postoperative infections after colonic<br />and rectal surgery, purulent diseases in the abdominal and pelvic<br />cavities)<br />&bull; gynaecologic infections (e. g. endometritis, after hysterectomy or<br />caesarean section, childbed fever, septic abortion)<br />&bull; infections in the ear-nose-throat and tooth-mouth-jaw regions<br />(e. g. PLAUT-VINCENT-angina)<br />&bull; bone and joint infections (e. g. osteomyelitis)<br />&bull; gas gangrene<br />&bull; septicaemia with thrombophlebitis.<br />In a mixed aerobic and anaerobic infection, antibiotics appropriate for<br />the treatment of the aerobic infection should be used in addition to<br />Metronidazole Intravenous Infusion 5 mg/ml.<br />A prophylactic use is always indicated prior to operations with a<br />high risk of anaerobic infections (gynaecologic and intra-abdominal<br />operations).<br />Consideration should be given to official guidance on the appropriate<br />use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage is adjusted according to the patient&rsquo;s individual response<br />to therapy, her/his age and body weight and according to nature and<br />severity of the disease.<br />The following dosage guidelines should be followed:</p><p>Adults and adolescents:<br /><u>Treatment of anaerobic infections</u><br />Usually a single dose of 1500 mg (300 ml) is given on the first day of<br />treatment followed by 1000 mg (200 ml) given as single doses on the<br />subsequent days.<br />Alternatively, 500 mg (100 ml) may be given every 8 hours. If medically<br />indicated a loading dose of 15 mg/kg body weight (BW) may be given<br />at the beginning of treatment<br />The duration of therapy is dependent on the effect of the treatment. In<br />most cases a treatment course of 7 days will be sufficient. If clinically<br />indicated, treatment may be continued beyond this time e.g. for the<br />eradication of infection from sites which cannot be drained or are<br />liable to endogenous recontamination by anaerobic pathogens from<br />the gut,oropharynx or genital tract. (See also section 4.4.)</p><p><u>Bacterial vaginosis:</u><br />Adolescents: 400mg twice daily for 5-7 days or 2000mg as a single<br />dose.</p><p><u>Urogenital trichomoniasis:</u><br />Adults and adolescents: 2000mg as a single dose or 200mg 3 times<br />daily for 7 days or 400mg twice daily for 5-7 days</p><p><u>Giardiasis:</u><br />&gt; 10 years: 2000mg once daily for 3 days, or 400mg three times daily<br />for 5 days, or 500mg twice daily for 7 to 10 days<br />Alternatively, as expressed in mg per kg of body weight: 15-40mg/kg/<br />day divided in 2-3 doses.</p><p><u>Amoebiasis:</u><br />&gt; 10 years: 400 to 800mg 3 times daily for 5-10 days<br />Alternatively, doses may be expressed by body weight: 35 to 50mg/kg<br />daily in 3 divided doses for 5 to 10 days, not to exceed 2400mg/day</p><p><u>Prophylaxis against post-operative infection caused by anaerobic<br />bacteria:</u><br />500 mg, with administration completed approximately one hour<br />before surgery. The dose is repeated after 8 and 16 hours. Oral doses<br />of 200 mg or 400 mg 8 hourly to be started as soon as feasible.</p><p><strong>Paediatric population</strong><br /><u>Treatment of anaerobic infections</u><br />&bull; Children &gt; 8 weeks to 12 years of age:<br />The usual daily dose is 20 &ndash; 30 mg per kg BW per day as a single<br />dose or divided into 7.5 mg per kg BW every 8 hours. The daily dose<br />may be increased to 40 mg per kg BW, depending on the severity of<br />the infection.<br />&bull; Children &lt; 8 weeks of age:<br />15 mg per kg BW as a single dose daily or divided into 7.5 mg per kg<br />BW every 12 hours.<br />&bull; In newborns with a gestation age &lt; 40 weeks,<br />accumulation of metronidazole can occur during the first week of<br />life; therefore the concentrations of metronidazole in serum should<br />preferably be monitored after a few days therapy.<br />Duration of treatment is usually 7 days.</p><p><u>Prophylaxis against postoperative infections caused by anaerobic<br />bacteria:</u><br />&bull; Children &lt; 12 years:<br />20 &ndash; 30 mg/kg BW as a single dose given 1 &ndash; 2 hours before surgery<br />&bull; Newborns with a gestation age &lt;40 weeks:<br />10 mg/kg BW as a single dose before surgery</p><p><u>Urogenital trichomoniasis:</u><br />Children &lt; 10 years: 40mg/kg orally as a single dose or 15-30 mg/kg/<br />day divided in 2-3<br />doses for 7 days; not to exceed 2000mg/dose</p><p><u>Giardiasis:</u><br />Children 7 to 10 years: 1000 mg once daily for 3 days<br />Chi ldren 3 to 7 years: 600 to 800mg once daily for 3 days<br />Chi ldren 1 to 3 years: 500mg once daily for 3 days<br />Alternatively, as expressed in mg per kg of body weight: 15-40mg/kg/<br />day divided in 2-3 doses.</p><p><u>Amoebiasis:</u><br />Children 7 to 10 years: 200 to 400mg 3 times daily for 5-10 days<br />Children 3 to 7 years: 100 to 200mg 4 times daily for 5-10 days<br />Children 1 to 3 years: 100 to 200mg 3 times daily for 5-10 days<br />Alternatively, doses may be expressed by body weight: 35 to 50mg/kg<br />daily in 3 divided doses for 5 to 10 days, not to exceed 2400mg/day</p><p><u>Eradication of Helicobacter pylori in paediatric patients:</u><br />As a part of a combination therapy, 20mg/kg/day not to exceed 500mg<br />twice daily for 7-14 days. Official guidelines should be consulted<br />before initiating therapy.</p><p><u>Patients with renal insufficiency</u><br />No dose reduction is required, see section 5.2.<br />In patients undergoing haemodialysis the conventional dose of<br />metronidazole should be scheduled after haemodialysis on dialysis<br />days to compensate the escape of metronidazole during the procedure.</p><p><u>Patients with hepatic insufficiency</u><br />As serum half-life is prolonged and plasma clearance is delayed in<br />severe hepatic insufficiency, patients with severe liver disease will<br />require lower doses (see section 5.2).<br />&nbsp;</p><p><strong>Method of administration</strong><br />Intravenous use.<br />The contents of one bottle are to be infused slowly i.v., i.e. 100 ml<br />max. over not less than 20 minutes, but normally over one hour.<br />Metronidazole Intravenous Infusion 5 mg/ml can also be diluted before<br />administration,<br />adding the medicinal product to an i.v. vehicle solution<br />such as 0.9 % sodium chloride or 5 % glucose infusion solution.<br />Concurrently prescribed antibiotics are to be administered separately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to metronidazole or other nitroimidazole derivatives
or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients with severe liver damage or impaired haematopoiesis (e. g.<br />granulocytopenia), metronidazole should only be used if its expected<br />benefits clearly outweigh potential hazards.<br />Due to the risk of aggravation, metronidazole should also be used<br />in patients with active or chronic severe peripheral and central<br />nervous system diseases only if its expected benefits clearly outweigh<br />potential hazards.<br />Convulsive seizures, myoclonus and peripheral neuropathy, the latter<br />mainly characterized by numbness or paresthesia of an extremity, have<br />been reported in patients treated with metronidazole. The appearance<br />of abnormal neurological signs demands the prompt evaluation of the<br />benefit/risk ratio of the continuation of therapy.<br />In the case of severe hypersensitivity reactions (e.g. anaphylactic shock),<br />treatment with Metronidazole Intravenous Infusion 5 mg/ml must be<br />discontinued immediately and established emergency treatment must<br />be initiated by qualified healthcare professionals.<br />Severe persistent diarrhoea occurring during treatment or during<br />the subsequent weeks may be due to pseudomembranous colitis<br />(in most cases caused by clostridium difficile), see section 4.8. This<br />intestinal disease, precipitated by the antibiotic treatment, may be<br />life-threatening and requires immediate appropriate treatment. Antiperistaltic<br />medicinal products must not be given.<br />The duration of therapy with metronidazole or drugs containing<br />other nitroimidazoles should not exceed 10 days. Only in specific<br />elective cases and if definitely needed, the treatment period may<br />be extended, accompanied by appropriate clinical and laboratory<br />monitoring. Repeat therapy should be restricted as much as possible<br />and to specific elective cases only. These restrictions must be observed<br />strictly because the possibility of metronidazole developing mutagenic<br />activity cannot be safely excluded and because in animal experiments<br />an increase of the incidence of certain tumours has been noted.<br />Cases of severe hepatotoxicity/acute hepatic failure, including cases<br />with a fatal outcome with very rapid onset after treatment initiation<br />in patients with Cockayne syndrome have been reported with products<br />containing metronidazole for systemic use. In this population,<br />metronidazole should therefore be used after careful benefit-risk<br />assessment and only if no alternative treatment is available. Liver<br />function tests must be performed just prior to the start of therapy,<br />throughout and after end of treatment until liver function is within<br />normal ranges, or until the baseline values are reached. If the liver<br />function tests become markedly elevated during treatment, the drug<br />should be discontinued.<br />Patients with Cockayne syndrome should be advised to immediately<br />report any symptoms of potential liver injury to their physician and<br />stop taking metronidazole. Prolonged therapy with metronidazole may<br />be associated with bone marrow depression, leading to an impairment<br />of haematopoiesis. Manifestations see section 4.8. Blood cell counts<br />should be carefully monitored during prolonged therapy.<br />Special warnings/precautions regarding excipients<br />This medicinal product contains 3.22 mg sodium per ml, equivalent<br />to 0.16 % of the WHO recommended maximum daily intake of 2 g<br />sodium for an adult.</p><p><u>Interference with laboratory tests</u><br />Metronidazole interferes with the enzymatic-spectrophotometric<br />determination of aspartate aminotransferase (AST), alanine<br />aminotransferase (ALT), lactate dehydrogenase (LDH), triglycerides<br />and glucose hexokinase resulting in decreased values (possibly down<br />to zero).<br />Metronidazole has a high absorbance at the wavelength at<br />which nicotinamide-adenine dinucleotide (NADH) is determined.<br />Therefore elevated liver enzyme concentrations may be masked by<br />metronidazole when measured by continuous-flow methods based<br />on endpoint decrease in reduced NADH. Unusually low liver enzyme<br />concentrations, including zero values, have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Amiodarone</u><br />QT interval prolongation and torsade de pointes have been reported<br />with the coadministration of metronidazole and amiodarone. It may<br />be appropriate to monitor QT interval on the ECG if amiodarone is<br />used in combination with metronidazole. Patients treated on an<br />outpatient basis should be advised to seek medical attention if they<br />experience symptoms that could indicate the occurrence of torsade<br />de pointes such as dizziness, palpitations, or syncope.<br /><u>Barbiturates</u><br />Phenobarbital may increase the hepatic metabolism of metronidazole,<br />reducing its plasma half life to 3 hours.<br /><u>Busulfan</u><br />Coadministration with metronidazole may significantly increase the<br />plasma concentrations of busulfan. The mechanism of interaction<br />has not been described. Due to the potential for severe toxicity<br />and mortality associated with elevated busulfan plasma levels,<br />concomitant use with metronidazole should be avoided.<br /><u>Carbamazepine</u><br />Metronidazole may inhibit the metabolism of carbamazepine and<br />raise the plasma concentrations as a consequence.<br /><u>Cimetidine</u><br />Concurrently administered cimetidine may reduce the elimination of<br />metronidazole in isolated cases and subsequently lead to increased<br />metronidazole concentrations in serum.<br /><u>Contraceptive drugs</u><br />Some antibiotics can, in some exceptional cases, decrease the effect<br />of contraceptive pills by interfering with the bacterial hydrolysis<br />of steroid conjugates in the intestine and hereby reduce the reabsorption<br />of unconjugated steroid. Therefore the plasma levels of<br />the active steroid decrease. This unusual interaction can occur in<br />women with a high excretion of steroid conjugates through the bile.<br />There are case reports of oral contraceptive failure in association with<br />different antibiotics, e.g. ampicillin, amoxicillin, tetracyclines and also<br />metronidazole.<br /><u>Vitamin K antagonists</u><br />Concomitant treatment with metronidazole may potentiate the<br />anticoagulant effect of vitamin K antagonists, e.g. coumarin<br />derivatives, and increase the risk for bleeding as a consequence of<br />decreased hepatic degradation. Dose adjustment of the anticoagulant<br />can be necessary.<br /><u>Ciclosporine</u><br />During simultaneous therapy with cyclosporine and metronidazole<br />there is a risk for increased serum concentrations of cyclosporine.<br />Frequent monitoring of cyclosporine and creatinine is required.<br /><u>Disulfiram</u><br />Simultaneous administration of disulfiram may cause states of<br />confusion or even psychotic reactions. Combination of both agents<br />must be avoided.<br /><u>Fluorouracil</u><br />Metronidazole inhibits the metabolism of concurrently administered<br />fluorouracil, i.e. the plasma concentration of fluorouracil is increased.<br /><u>Lithium</u><br />Caution is to be exercised when metronidazole is administered<br />simultaneously with lithium salts, because under metronidazole<br />therapy raised serum concentrations of lithium have been observed.<br /><u>Mycophenolate mofetil</u><br />Substances that alter the gastrointestinal flora (e.g., antibiotics)<br />may reduce the oral bioavailability of mycophenolic acid products.<br />Close clinical and laboratory monitoring for evidence of diminished<br />immunosuppressive effect of mycophenolic acid is recommended<br />during concomitant therapy with anti-infective agents.<br /><u>Phenytoin</u><br />Metronidazole inhibits the metabolism of concurrently administered<br />phenytoin, i.e. the plasma concentration of phenytoin is increased.<br />On the other hand, the efficacy of metronidazole is reduced when<br />phenytoin is administered concurrently.<br /><u>Tacrolimus</u><br />Coadministration with metronidazole may increase the blood<br />concentrations of tacrolimus. The proposed mechanism is inhibition<br />of hepatic tacrolimus metabolism via CYP 3A4. Tacrolimus blood<br />levels and renal function should be checked frequently and the<br />dosage adjusted accordingly, particularly following initiation or<br />discontinuation of metronidazole therapy in patients who are<br />stabilized on their tacrolimus regimen.<br /><strong>Other forms of interaction</strong><br /><u>Alcohol</u><br />Intake of alcoholic beverages must be avoided during metronidazole<br />therapy since adverse reactions such as dizziness and vomiting may<br />occur (disulfiram-like effect).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraception in males and females<br />See section 4.5 &lsquo;contraceptive drugs&rsquo;<br /><strong><u>Pregnancy</u></strong><br />The safety of the use of metronidazole during pregnancy has not<br />sufficiently been demonstrated. In particular, reports on the use<br />during early pregnancy are contradictory. Some studies indicated an<br />increased rate of malformations. In animal experiments metronidazole<br />did not show teratogenic effects (see section 5.3).<br />During the first trimester, Metronidazole Intravenous Infusion 5 mg/ml<br />should only be used to treat severe life-threatening infections, if there is<br />no safer alternative. During the second and third trimester, Metronidazole<br />Intravenous Infusion 5 mg/ml may also be used to treat other infections<br />if its expected benefits clearly outweigh any possible risk.<br />Pregnancy Category B<br /><strong><u>Breast-feeding</u></strong><br />Since metronidazole is secreted into breastmilk, nursing is to be<br />interrupted during therapy. Also after the end of the therapy with<br />metronidazole, nursing should not be resumed before another 2 &ndash; 3<br />days because of the prolonged half-life period of metronidazole.<br /><strong><u>Fertility</u></strong><br />Animal studies only indicate a potential negative influence of<br />metronidazole on the male reproductive system if high doses lying<br />well above the maximum recommended dose for humans were<br />administered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Even when used as directed, metronidazole may alter reactivity so far<br />that the ability to drive or to use machinery is impaired. This holds<br />true to still a higher degree in combination with alcohol intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects are mainly associated with prolonged use or high<br />doses. The most commonly observed effects include nausea, abnormal<br />taste sensations and the risk of neuropathy in case of long term<br />treatment.</p><p>In the following listing, for the description of the frequencies of<br />undesirable effects the following terms are used:<br />Very common : &ge; 1/10<br />Common : &ge; 1/100 to &lt; 1/10<br />Uncommon : &ge; 1/1,000 to &lt; 1/100<br />Rare : &ge; 1/10,000 to &lt; 1/1,000<br />Very rare : &lt; 1/10,000<br />Not known : (Frequency cannot be estimated from the available<br />data)</p><p><u>Infections and infestations</u><br /><u>Common:</u> Superinfections with candida (e.g. genital infections)<br /><u>Rare: </u>Pseudomembranous colitis, which may occur during or<br />after therapy, manifesting as severe persistent diarrhoea.<br />Details regarding emergency treatment see section 4.4.</p><p><u>Blood and lymphatic system disorders</u><br /><u>Very rare:</u> During therapy with metronidazole, decreases of<br />leukocyte and platelet counts (granulocytopenia,<br />agranulocytosis, pancytopenia and thrombocytopenia)<br /><u>Not known: </u>Leucopenia, aplastic anaemia.<br />During prolonged administration regular monitoring of blood cell<br />counts is mandatory.</p><p><u>Immune system disorders</u><br /><u>Rare: </u>Severe acute systemic hypersensitivity reactions:<br />anaphylaxis, up to anaphylactic shock.<br />Severe skin reactions, see &ldquo;Skin and subcutaneous<br />disorders&rdquo; below.<br />These severe reactions demand immediate therapeutic<br />intervention.<br /><u>Not known:</u> Mild to moderate hypersensitivity reactions, e. g. skin<br />reactions (see &ldquo;Skin and subcutaneous disorders&rdquo; below)<br />angioedema.</p><p><u>Metabolism and nutrition disorders</u><br /><u>Not known:</u> Anorexia</p><p><u>Psychiatric disorders</u><br /><u>Very rare:</u> Psychotic disorders, including states of confusion,<br />hallucination<br /><u>Not known:</u> Depression</p><p><u>Nervous system disorders</u><br /><u>Very rare:</u> Encephalopathy, headache, fever, drowsiness, dizziness,<br />disturbances in sight and movement, vertigo, ataxia,<br />dysarthria, convulsions.<br /><u>Not known:</u> Somnolence or insomnia, myoclonus, seizures, peripheral<br />neuropathy manifesting as paraesthesia, pain, furry<br />sensation, and tingling in the extremities<br />Aseptic meningitis</p><p>If seizures or signs of peripheral neuropathy or encephalopathy<br />appear, the attending doctor should be informed immediately.</p><p><u>Eye disorders</u><br /><u>Very rare</u>: Disturbance of vision, e.g. diplopia, myopia.<br /><u>Not known: </u>Oculogyric crisis, optic neuropathy/neuritis (isolated<br />cases)</p><p><u>Cardiac disorders</u><br /><u>Rare: </u>ECG changes like flattening of T-wave</p><p>Gastro-intestinal disorders<br /><u>Not known: </u>Vomiting, nausea, diarrhoea, glossitis and stomatitis,<br />eructation with bitter taste, epigastric pressure, metallic<br />taste, furred tongue.<br />Dysphagia (caused by central nervous effects of metronidazole), pancreatitis.</p><p><u>Hepatobiliary disorders</u><br /><u>Very rare: </u>Abnormal values of hepatic enzymes and bilirubin<br />Hepatitis, jaundice</p><p><u>Skin and subcutaneous tissue disorders</u><br /><u>Very rare: </u>Allergic skin reactions, e. g. pruritus, urticaria<br />Stevens-Johnson syndrome ,toxic epidermal necrolysis<br />(isolated reports)</p><p><strong>The two latter reactions demand immediate<br />therapeutic intervention</strong><br /><u>Not known: </u>erythema multiforme</p><p><u>Musculoskeletal and, connective tissue disorders</u><br /><u>Very rare:</u> Arthralgia, myalgia</p><p><u>Renal and urinary disorders</u><br /><u>Uncommon:</u> Dark coloured urine (due to a metabolite of metronidazole)</p><p><u>General disorders and administration site conditions<br />Not known:</u> Vein irritations (up to thrombophlebitis) after intravenous administration states of weakness, fever</p><p><strong>Paediatric population</strong><br />Frequency, type and severity of adverse reactions in children are the<br />same as in adults.</p><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorisation of the<br />medicinal product is important. It allows continued monitoring<br />of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions to<br /><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong><br />As signs and symptoms of overdose the undesirable effects described<br />under section 4.8 may appear.<br /><strong>Treatment</strong><br />There is no specific treatment or antidote that can be applied in the<br />case of gross overdose of metronidazole. If required, metronidazole<br />can be effectively eliminated by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Anti-infectives for systemic use &ndash;<br />imidazole derivatives<br />ATC Code: J01X D01</p><p>Mechanism of action<br />Metronidazole itself is ineffective. It is a stable compound able to<br />penetrate into microorganisms. Under anaerobic conditions nitroso<br />radicals acting on DNA are formed from metronidazole by the<br />microbial pyruvate-ferredoxin-oxidoreductase, with oxidation of<br />ferredoxin and flavodoxin. Nitroso radicals form adducts with base<br />pairs of the DNA, thus leading to breaking of the DNA chain and<br />consecutively to cell death.</p><p>PK/PD relationship<br />The efficacy of metronidazole mainly depends on the quotient of the<br />maximum serum concentration (cmax) and the minimum inhibitory<br />concentration (MIC) relevant for the microorganism concerned.</p><p>Breakpoints<br />For the testing of metronidazole usual dilution series are applied. The<br />following minimum inhibitory<br />concentration have been established to distinguish susceptible from<br />resistant microorganisms:<br />EUCAST (European Committee on Antimicrobial Susceptibility Testing)<br />breakpoints separating susceptible (S) from resistant organisms (R) are<br />as follows:<br />Gram-positive anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)<br />Gram-negative anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)<br />List of susceptible and resistant organisms.<br />Source: Zentralstelle f&uuml;r die Auswertung von Resistenzdaten (Z.A.R.S.)<br />bei systemisch wirkenden Antibiotika, Germany, January 2011</p><p>Pharmaco-therapeutic group: Anti-infectives for systemic use &ndash;<br />imidazole derivatives<br />ATC Code: J01X D01<br />Mechanism of action<br />Metronidazole itself is ineffective. It is a stable compound able to<br />penetrate into microorganisms. Under anaerobic conditions nitroso<br />radicals acting on DNA are formed from metronidazole by the<br />microbial pyruvate-ferredoxin-oxidoreductase, with oxidation of<br />ferredoxin and flavodoxin. Nitroso radicals form adducts with base<br />pairs of the DNA, thus leading to breaking of the DNA chain and<br />consecutively to cell death.<br />PK/PD relationship<br />The efficacy of metronidazole mainly depends on the quotient of the<br />maximum serum concentration (cmax) and the minimum inhibitory<br />concentration (MIC) relevant for the microorganism concerned.<br />Breakpoints<br />For the testing of metronidazole usual dilution series are applied. The<br />following minimum inhibitory<br />concentration have been established to distinguish susceptible from<br />resistant microorganisms:<br />EUCAST (European Committee on Antimicrobial Susceptibility Testing)<br />breakpoints separating susceptible (S) from resistant organisms (R) are<br />as follows:<br />Gram-positive anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)<br />Gram-negative anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)<br />List of susceptible and resistant organisms.<br />Source: Zentralstelle f&uuml;r die Auswertung von Resistenzdaten (Z.A.R.S.)<br />bei systemisch wirkenden Antibiotika, Germany, January 2011</p><p>Pharmaco-therapeutic group: Anti-infectives for systemic use &ndash;<br />imidazole derivatives<br />ATC Code: J01X D01<br />Mechanism of action<br />Metronidazole itself is ineffective. It is a stable compound able to<br />penetrate into microorganisms. Under anaerobic conditions nitroso<br />radicals acting on DNA are formed from metronidazole by the<br />microbial pyruvate-ferredoxin-oxidoreductase, with oxidation of<br />ferredoxin and flavodoxin. Nitroso radicals form adducts with base<br />pairs of the DNA, thus leading to breaking of the DNA chain and<br />consecutively to cell death.<br />PK/PD relationship<br />The efficacy of metronidazole mainly depends on the quotient of the<br />maximum serum concentration (cmax) and the minimum inhibitory<br />concentration (MIC) relevant for the microorganism concerned.<br />Breakpoints<br />For the testing of metronidazole usual dilution series are applied. The<br />following minimum inhibitory<br />concentration have been established to distinguish susceptible from<br />resistant microorganisms:<br />EUCAST (European Committee on Antimicrobial Susceptibility Testing)<br />breakpoints separating susceptible (S) from resistant organisms (R) are<br />as follows:<br />Gram-positive anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)<br />Gram-negative anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)<br />List of susceptible and resistant organisms.<br />Source: Zentralstelle f&uuml;r die Auswertung von Resistenzdaten (Z.A.R.S.)<br />bei systemisch wirkenden Antibiotika, Germany, January 2011</p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><strong>Commonly susceptible species</strong></td></tr><tr><td>&nbsp; <strong>Anaerobes</strong></td></tr><tr><td>&nbsp; &nbsp; Bacteroides fragilis=</td></tr><tr><td>&nbsp; &nbsp; Clostridium difficile</td></tr><tr><td>&nbsp; &nbsp; Clostridium perfringens</td></tr><tr><td>&nbsp; &nbsp; Fusobacterium spp.</td></tr><tr><td>&nbsp; &nbsp; Peptoniphilus spp.</td></tr><tr><td>&nbsp; &nbsp; Peptostreptococcus spp.</td></tr><tr><td>&nbsp; &nbsp; Porphyromonas spp.</td></tr><tr><td>&nbsp; &nbsp; Prevotella spp.</td></tr><tr><td>&nbsp; &nbsp; Veillonella spp.</td></tr><tr><td>&nbsp; <strong>Other micro-organismsp.</strong></td></tr><tr><td>&nbsp; &nbsp; Entamoeba histolytica</td></tr><tr><td>&nbsp; &nbsp; Gardnerella vaginalis.</td></tr><tr><td>&nbsp; &nbsp; Giardia lamblia.</td></tr><tr><td><p>&nbsp; &nbsp; Trichomonas vaginalis.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><strong>Species for which acquired resistance may be a problem</strong></td></tr><tr><td>&nbsp; <strong>Gram-negative aerobes</strong></td></tr><tr><td>&nbsp; &nbsp; &nbsp;Helicobacter pylori</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><strong>Inherently resistant organisms</strong></td></tr><tr><td>&nbsp; &nbsp; &nbsp; All obligate aerobes&nbsp;</td></tr><tr><td>&nbsp;<strong> &nbsp;Gram-positive micro-organismss</strong></td></tr><tr><td>&nbsp; &nbsp; &nbsp; &nbsp;Enterococcus spp.</td></tr><tr><td>&nbsp; &nbsp; &nbsp; &nbsp;Staphylococcus spp.</td></tr><tr><td>&nbsp; &nbsp; &nbsp; &nbsp;Streptococcus spp.</td></tr><tr><td>&nbsp; &nbsp; <strong>Gram-negative micro-organismss</strong></td></tr><tr><td>&nbsp; &nbsp; &nbsp; &nbsp;Enterobacteriaceae</td></tr><tr><td>&nbsp; &nbsp; &nbsp; &nbsp;Haemophilus spp.</td></tr></tbody></table><p>&nbsp;</p><p>- At the time of publication of these tables, no up-to-date data<br />were available. In primary literature, standard reference books and<br />therapy recommendations susceptibility of the respective strains is<br />assumed.<br />- Only to be used in patients with allergy to penicillin</p><p><u>Mechanisms of resistance to metronidazole</u><br />The mechanisms of metronidazole resistance are still understood only<br />in part.<br />In H.pylori resistance to metronidazole is caused by mutations of a<br />gene that encodes NADPH nitroreductase. These mutations lead to<br />an exchange of amino acids, rendering the enzyme inactive. Thus the<br />step of activation of metronidazole to the active nitroso radical does<br />not take place.<br />Strains of Bacteroides being resistant to metronidazole possess genes<br />encoding nitroimidazole reductases converting nitroimidazoles to<br />aminoimidazoles. Therefore the formation of the antibacterially<br />effective nitroso radicals is inhibited.<br />There is full cross resistance between metronidazole and the other<br />nitroimidazole derivatives (tinidazole, ornidazole, nimorazole).<br />The prevalence of acquired resistance of individual species may vary,<br />depending on region and time. Therefore especially for the adequate<br />treatment of severe infections specific local information regarding<br />resistance should be available. If there is doubt about the efficacy<br />of metronidazole due to the local resistance situation, expert advice<br />should be sought. Especially in the case of severe infections or failure<br />of treatment, microbiological diagnosis including determination of<br />species of the microorganism and its susceptibility to metronidazole<br />is required</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption:</u><br />Since Metronidazole Intravenous Infusion 5 mg/ml is infused<br />intravenously the bioavailability is 100%.<br /><u>Distribution:</u><br />Metronidazole is widely distributed in body tissues after injection.<br />Metronidazole appears in most body tissues and fluids including<br />bile, bone, cerebral abscess, cerebro-spinal fluid, liver, saliva, seminal<br />fluid, and vaginal secretions, and achieves concentrations similar to<br />those in plasma. It also diffuses across the placenta, and is found in<br />breast milk of nursing mothers in concentrations equivalent to those<br />in serum. Protein binding is less than 20 %, the apparent volume of<br />distribution is 36 litres.<br /><u>Biotransformation:</u><br />Metronidazole is metabolised in the liver by side-chain oxidation<br />and glucuronide formation. Its metabolites include an acid oxidation<br />product, a hydroxy derivative and glucuronide. The major metabolite<br />in the serum is the hydroxylated metabolite, the major metabolite in<br />the urine is the acid metabolite.<br /><u>Elimination:</u><br />Approximately 80% of the substance is excreted in urine with less<br />than 10% in the form of the unchanged drug substance. Small<br />quantities are excreted via the liver. Elimination half-life is 8 (6-10)<br />hours.<br /><u>Paediatric population</u><br />See section 4.2.<br /><u>Characteristics in special patient groups:</u><br />Renal insufficiency delays excretion only to an unimportant degree.<br />Delayed plasma clearance and prolonged serum half-life (up to 30 h)<br />is to be expected in severe liver disease</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Single-dose toxicity</u><br />The lowest published toxic dose for intravenously administered<br />Metronidazole has been referred to as 30 mg/kg BW.</p><p><u>Repeated dose toxicity</u><br />In dogs, toxic effects after repeated administration appeared in the<br />form of ataxia and tremor. In investigations in monkeys a dosedependent<br />increase of hepatocellular degeneration was demonstrated<br />after administration over one year.</p><p><u>Mutagenic and tumorigenic potential</u><br />Metronidazole has been shown to be carcinogenic in the mouse<br />and in the rat following chronic oral administration however similar<br />studies in the hamster have given negative results. Epidemiological<br />studies have provided no clear evidence of an increased carcinogenic<br />risk in humans.<br />Metronidazole has been shown to be mutagenic in bacteria in vitro. In<br />studies conducted in mammalian cells in vitro. as well as in rodent or<br />humans in vivo, there was inadequate evidence of a mutagenic effect<br />of metronidazole, with some studies reporting mutagenic effects,<br />while others studies were negative.</p><p><u>Reproduction toxicity</u><br />No teratogenic or other embryotoxic effects have been observed in<br />investigations with rats and rabbits.<br />After repeated administration of metronidazole over 26 &ndash; 80 weeks to<br />rats, testicular and prostatic dystrophy has only been observed with<br />high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride,<br />Disodium phosphate dodecahydrate,<br />Citric acid monohydrate,<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal<br />products except mentioned in section 6.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened
3 years.

after first opening the container
Unused contents must be discarded and not be stored for later use.

after dilution according to directions
From a microbiological point of view, dilutions should be used
immediately. If not used immediately, in-use storage times and
conditions prior to use are the responsibility of the user and would
normally not be longer than 24 hours at 2 to 8 °C, unless dilution has
taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the container in the outer carton in order to protect from light.<br />Storage conditions for diluted medicinal product see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product is supplied in:<br />&ndash; bottles of low-density polyethylene, contents: 100 ml,<br />available in packs of 10 x 100 ml, 20 x 100 ml</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p><p><u>Other handling instructions:</u><br />For single use only. Discard container and any unused contents after<br />use.</p><p>The product can be diluted in sodium chloride 0.9 % w/v or glucose<br />5 % w/v solutions for infusion. For dilution procedures the usual<br />precautions of asepsis must be adhered to.</p><p>Only to be used if solution is clear and colourless or slightly yellowish<br />and the container and its closure do not show visible signs of damage</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                B. Braun Melsungen AG
Carl-Braun-Straße 1
34212 Melsungen, Germany

Postal address:
34209 Melsungen, Germany

Phone: +49/5661/71-0
Fax: +49/5661/71-4567
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>